Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

NCT02341911 | Unknown Phase 2

• 1 other identifier: Fudan BR2015-16
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)

Conditions

Breast Cancer

Keywords

triple negative breast cancer; fine line chemotherapy

Outcome Measures

Primary Outcomes (1)

• PFS (Progression Free Survival)

  6 weeks

Secondary Outcomes (3)

• Objective Response Rate (ORR)

  6 weeks

• Number of Participants with Adverse Events as a Measure of Safety and Tolerability

  6 weeks

• Overall Survival (OS)

  From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Study Arms (2)

Gemcitabine,cisplatin

EXPERIMENTAL

GP (gemcitabine and cisplatin combination)

Drug: Gemcitabine,cisplatin

Gemcitabine,carboplatin

ACTIVE COMPARATOR

GC (gemcitabine and carboplatin combination)

Drug: Gemcitabine,carboplatin

Interventions

Gemcitabine,cisplatin DRUG

Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1

Also known as: experimental arm

Gemcitabine,cisplatin

Gemcitabine,carboplatin DRUG

Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1

Also known as: control arm

Gemcitabine,carboplatin

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histological proven unresectable recurrent or advanced breast cancer, including de novo stage IV disease.
• Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human epithelial receptor-2 (HER2) by immunohistochemistry (ER \<1%, PR \<1% and Her2 negative). A negative Her2 gene amplification should be verified by FISH test for those patients with Her2 (2+). For those with Her2 (1+), FISH test might be considered by the investigator.
• No prior chemotherapy for metastatic breast cancer is permitted. Prior administration of chemotherapy in the adjuvant/neoadjuvant setting is acceptable if completed 6 months before the enrollment.
• At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST 1.1)
• Performance status no more than 1
• All patients enrolled are required to have adequate hematologic, hepatic, and renal function
• Life expectancy longer than 12 weeks
• No serious medical history of heart, lung, liver and kidney
• Be able to understand the study procedures and sign informed consent.
• Patients with good compliance

You may not qualify if:

• Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days before the first day of drug dosing, or, if positive, a pregnancy should be ruled out by ultrasound)
• Women of child-bearing potential, unwilling to use adequate contraceptive protection during the process of the study
• Treatment with radiotherapy at the axial skeleton within 4 weeks before the first treatment or has not recovered from all toxicities of previous radiotherapy
• Treatment with an investigational product within 4 weeks before the first treatment
• Patients with symptomatic central nervous system metastases are not permitted, except for those with stable and asymptomatic brain metastases who have completed cranial irradiation, and have at least one measurable lesion outside the brain. Radiotherapy should be completed within 4 weeks prior to the registration
• Other active malignancies (including other hematologic malignancies) or other malignancies within the last 5 years, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.
• Patients having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions
• Uncontrolled serious infection

Sponsors & Collaborators

• Fudan University: lead

Study Sites (1)

Fudan University Cancer Hospital

Shanghai, 200032, China

RECRUITING

Related Publications (1)

• Wang B, Zhao Y, Li Y, Xu Y, Chen Y, Jiang Q, Yao D, Zhang L, Hu X, Fu C, Zhang S, Chen S. A plasma SNORD33 signature predicts platinum benefit in metastatic triple-negative breast cancer patients. Mol Cancer. 2022 Jan 18;21(1):22. doi: 10.1186/s12943-022-01504-0. No abstract available.

  PMID: 35042534 DERIVED

MeSH Terms

Conditions

Breast Neoplasms; Triple Negative Breast Neoplasms

Interventions

Gemcitabine; Cisplatin; Carboplatin

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Chlorine Compounds; Inorganic Chemicals; Nitrogen Compounds; Platinum Compounds; Coordination Complexes; Organic Chemicals

Study Officials

• Xichun Hu, MD, PhD

  Fudan University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xichun Hu, MD, PhD

CONTACT

64175590; huxicun@gmail.com

Biyun Wang, MD

CONTACT

64175590; pro_wangbiyun@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr

Study Record Dates

• First Submitted: January 13, 2015
• First Posted: January 19, 2015
• Study Start: January 1, 2015
• Primary Completion: December 1, 2022
• Study Completion: December 1, 2022
• Last Updated: April 20, 2022

Record last verified: 2022-04

Locations

CN (1)